Frauenklinik und Poliklinik
Refine
Has Fulltext
- yes (74)
Is part of the Bibliography
- yes (74)
Year of publication
Document Type
- Journal article (71)
- Doctoral Thesis (3)
Language
- English (74) (remove)
Keywords
- breast cancer (17)
- ovarian cancer (8)
- 3D printing (4)
- expression (4)
- gynecology (4)
- CD39 (3)
- CD73 (3)
- education (3)
- immune escape (3)
- inflammation (3)
- ketogenic diet (3)
- survival (3)
- teaching (3)
- Akt (2)
- BRENDA (2)
- Eierstockkrebs (2)
- Ketogenic diet (2)
- Metastatic breast cancer (2)
- NSG (2)
- T cells (2)
- VEGF (2)
- adenosine (2)
- apoptosis (2)
- autophagy (2)
- blood-brain barrier (2)
- cancer (2)
- cancer detection and diagnosis (2)
- cytokines (2)
- disease (2)
- gene (2)
- humanized mice (2)
- lymph nodes (2)
- pelvic examination (2)
- pelvic palpation (2)
- pregnancy (2)
- stress (2)
- trastuzumab (2)
- tumor stem cells (2)
- visualization (2)
- 2-APB (1)
- 3D tissue model (1)
- ADCC (1)
- Adenosin (1)
- Astrocytic tumor (1)
- Axonal degeneration (1)
- B7-H1 (1)
- Blood–brain barrier (1)
- Blut (1)
- CD74 (1)
- COVID-19 (1)
- CX3CL1 (1)
- CXCL13 (1)
- Ca2+ release activated Ca2+ channel (1)
- Chirurgie (1)
- Coronavirus Disease 2019 (1)
- Cortison (1)
- Covid-19 (1)
- DNA repair protraction (1)
- Dendritische Zelle (1)
- Diabetic polyneuropathy (1)
- Eierstocktumor (1)
- Endogenous Glucocorticoids (1)
- Epidural Analgesia (1)
- Expression (1)
- FDM (1)
- FWGE (1)
- Fettgehalt (1)
- Genetic causes of cancer (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- HER2 (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HERV-K (1)
- HLA class II (1)
- HLA peptidome (1)
- HLA-G (1)
- Health care service research (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- High fat diet (1)
- Human endogenous retrovirus (1)
- Immunsuppression (1)
- In vitro models (1)
- Ketogene Kost (1)
- Krebs <Medizin> (1)
- Krebskranker (1)
- L. reuteri (1)
- LPS (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Large loop excision of the transformation zone (LLETZ) (1)
- Lebensqualität (1)
- Loop electrosurgical excision procedure (LEEP) (1)
- MMP (1)
- MRSA (1)
- MRSA - methicillin-resistant Staphylococcus aureus (1)
- Matrix metalloproteinases (1)
- Medicine (1)
- Medizin (1)
- Molecular biology (1)
- Motor nerve biopsy (1)
- NRG1 (1)
- NSG-SGM3 (1)
- NVP-BEZ235 (1)
- Nectin‐2 (1)
- Neuropathy (1)
- Neurotrophic factors (1)
- Non-coding RNAs (1)
- Novel PI3K (1)
- Ovarialkarzinom (1)
- Ovarian Cancer (1)
- PC-1 blockade (1)
- PCR analysis (1)
- PD-1 (1)
- PD-L1 (1)
- Parkinson’s disease (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Patient-centered registry (1)
- Patient’s needs (1)
- Pelvisio® (1)
- RT-qPCT (1)
- Remifentanil (1)
- SH-6 (1)
- SLA (1)
- SOCE (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- T-DM1 (1)
- TGF-beta (1)
- TKTL1 (1)
- Toll-like receptor signaling (1)
- UME6 (1)
- VE-cadherin (1)
- accessibility (1)
- acute respiratory distress syndrome (1)
- advanced breast cancer (1)
- age factors (1)
- aged (1)
- aged 80 and over (1)
- animal models (1)
- anti-hormonal therapy (1)
- anti-tumor effects (1)
- argeted therapy (1)
- ascites (1)
- astrocytic tumor (1)
- astrocytoma (1)
- axillary dissection (1)
- bacteria (1)
- bacterial infection model (1)
- benzoquinone (1)
- bioimpedance analysis (1)
- bioinformatics (1)
- biomarker (1)
- bioreactor culture (1)
- blood lipids; fat loss; running performance (1)
- blood-brain barrier (BBB) model (1)
- bone metastases (1)
- brain metastases (1)
- brain metastasis (1)
- brain-metastasis (1)
- breast cancer imaging (1)
- breast cancer metastases (1)
- breast cancer subtypes (1)
- cachexia (1)
- calprotectin (1)
- cancer cell lines (1)
- cancer cells (1)
- cancer chemotherapy (1)
- cancer dissemination (1)
- cancer microenvironment (1)
- cancer patients (1)
- cancer risk factors (1)
- cancer stem cell immunology (1)
- cancer stem cells (1)
- cancer treatment (1)
- cell lung cancer (1)
- cervical dysplasia (1)
- chemotherapy (1)
- chronic periodontitis (1)
- claudin 5 (1)
- co-culture (1)
- combinatorial drug predictions (1)
- common variable immunodeficiency (CVID) (1)
- conventional imaging (1)
- cord blood (1)
- cross-sectional imaging (1)
- cytostatic (1)
- cytotoxicity (1)
- delay of therapy (1)
- dendritic cells (1)
- diseases of the nervous system (1)
- dysplasia (1)
- endocrine therapy (1)
- epidemiology (1)
- evidence‐based medicine (1)
- exercise (1)
- exosomes (1)
- expression pattern (1)
- feasibility (1)
- fecal short-chain fatty acids (1)
- female (1)
- fiber intake (1)
- follow up (1)
- fused deposition modeling (FDM) (1)
- gene expression (1)
- genetic testing (1)
- genital warts (1)
- geographic information science (1)
- glioblastoma (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (1)
- glioblastoma stem cell (1)
- glioma (1)
- gliomas (1)
- glucose (1)
- growth (1)
- growth differentiation factor 15 (1)
- guideline adherent treatment (1)
- gynecologic surgical procedures/methods (1)
- health care providers (1)
- health care service research (1)
- histology (1)
- histopathology (1)
- hormona therapy (1)
- hormones (1)
- human genetics (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human papillomavirus (1)
- humanized hemato-lymphoid mice (1)
- hyaluronan-related enzymes (1)
- hypoxia (1)
- immune response (1)
- immunohistochemistry (1)
- immunoresistance (1)
- immunosurveillance (1)
- immunotherapies (1)
- immunotherapy (1)
- implementation (1)
- inborn errors of immunity (IEIs) (1)
- individual mind state (1)
- inflammatory cascades (1)
- insulin (1)
- insulin-like growth factor 1 (IGF1) (1)
- intestinal inflammation (1)
- intestinal permeability (1)
- invasiveness (1)
- ionizing radiation (1)
- ketogenic dients (1)
- ketone bodies (1)
- laparoscopy/methods (1)
- large loop excision of the transformation zone (LLETZ) (1)
- latency (1)
- lifestyle habits (1)
- low carb diet (1)
- low carbohydrate diet (1)
- lung-cancer (1)
- m-Health (1)
- mTOR Inhibitor (1)
- mammography (1)
- matrix metalloproteinase (1)
- medicine (1)
- melanoma (1)
- metabolic profile (1)
- metabolism (1)
- metastasis (1)
- miRNA (1)
- miRNAs (1)
- mice (1)
- microRNA (1)
- microarray (1)
- microbiota (1)
- microglia (1)
- microna profiles (1)
- middle Aged (1)
- modular tumor tissue models (1)
- monocyte (1)
- monocyte subsets (1)
- monocytes (1)
- morphogenesis (1)
- motivational level (1)
- mouse brain (1)
- multiple sclerosis (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- neoadjuvant therapies (1)
- neonatal immunology (1)
- neural stem cell (1)
- neurodegeneration (1)
- neurogenesis (1)
- neuroimmunology (1)
- neuroinflammation (1)
- neurological disorders (1)
- neurovascular unit in vitro (1)
- number of (1)
- ovarian carcinoma (1)
- p53 (1)
- pathways (1)
- patient safety (1)
- patient serum (1)
- pelvic organ prolapse/surgery (1)
- peripheral blood (1)
- peritoneal metastasis (1)
- pertuzumab (1)
- pilot study (1)
- plaque (1)
- polyvinylidene fluoride (PVDF) (1)
- positive nodal status (1)
- post-neoadjuvant therapies (1)
- postoperative complications/epidemiology (1)
- postpartum (1)
- prediction (1)
- pregnancy gingivitis (1)
- premalignant lesion (1)
- preterm infants (1)
- primary immunodeficiency (1)
- probiotic lozenges (1)
- prognosis (1)
- prognostic marker (1)
- psychological distress (1)
- quality of care (1)
- quality of life (1)
- radiosensibility (1)
- reactive oxygen species (1)
- reconstructive surgical procedures/methods (1)
- regulator (1)
- rehabilitation (1)
- retrospective Studies (1)
- review (1)
- rheumatoid arthritis (1)
- risk (1)
- robotic complications (1)
- robotic hysterectomy (1)
- robotic sacrocolpopexy (1)
- safety (1)
- score (1)
- seahorse (1)
- sentinel (1)
- serum (1)
- signature (1)
- simulation (1)
- skeleton (1)
- staib agar (1)
- staphylocccal infection/epidemiology (1)
- staphylococcal abscess (1)
- stromal hyaluronan (1)
- subgingival (1)
- subventricular zone (1)
- supportive care (1)
- surgical Mesh (1)
- survivors (1)
- symptom burden (1)
- transfer (1)
- transforming growth factor-beta-1 (1)
- trastuzumab deruxtecan (1)
- tumor associated macrophages (1)
- tumor dormancy (1)
- tumor immune escape (1)
- tumor immunology (1)
- tumor immunosurveillance (1)
- tumor infiltrating lymphocytes (1)
- tumor size (1)
- tumor-associated hyaluronan staining pattern (1)
- tumor-infiltrating lymphocytes (1)
- tumor-propagating cells (1)
- tumors (1)
- tumour immunology (1)
- ultrasound (1)
- unmet needs (1)
- urinary incontinence/surgery (1)
- uterine prolapse/surgery (1)
- vagina/surgery (1)
- vascular permeability (1)
- viral load (1)
- virtual (1)
- virulence (1)
- zonulin (1)
- β-Hydroxybutyrate (1)
Institute
- Frauenklinik und Poliklinik (74)
- Theodor-Boveri-Institut für Biowissenschaften (10)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (7)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (7)
- Kinderklinik und Poliklinik (4)
- Medizinische Klinik und Poliklinik II (4)
- Institut für Molekulare Infektionsbiologie (3)
- Institut für Virologie und Immunbiologie (3)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (3)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (3)
EU-Project number / Contract (GA) number
- 259867 (1)
Mechanisms underlying therapy resistance of tumor cells include protein kinase Akt. Putative Akt targets include store-operated \(Ca^{2+}\)-entry (SOCE) accomplished by pore forming ion channel unit Orai1 and its regulator STIM1. We explored whether therapy resistant (A2780cis) differ from therapy sensitive (A2780) ovary carcinoma cells in Akt, Orai1, and STIM1 expression, \(Ca^{2+}\)-signaling and cell survival following cisplatin (100µM) treatment. Transcript levels were quantified with RT-PCR, protein abundance with Western blotting, cytosolic \(Ca^{2+}\)-activity ([\(Ca^{2+}\)]i) with Fura-2-fluorescence, SOCE from increase of [\(Ca^{2+}\)]i following \(Ca^{2+}\)-readdition after Ca2+-store depletion, and apoptosis utilizing flow cytometry. Transcript levels of Orai1 and STIM1, protein expression of Orai1, STIM1, and phosphorylated Akt, as well as SOCE were significantly higher in A2780cis than A2780 cells. SOCE was decreased by Akt inhibitor III (SH-6, 10µM) in A2780cis but not A2780 cells and decreased in both cell lines by Orai1 inhibitor 2-aminoethoxydiphenyl borate (2-ABP, 50µM). Phosphatidylserine exposure and late apoptosis following cisplatin treatment were significantly lower in A2780cis than A2780 cells, a difference virtually abolished by SH-6 or 2-ABP. In conclusion, Orai1/STIM1 expression and function are increased in therapy resistant ovary carcinoma cells, a property at least in part due to enhanced Akt activity and contributing to therapy resistance in those cells.
Background: Tumor patients exhibit an increased peripheral demand of fatty acids and protein. Contrarily, tumors utilize glucose as their main source of energy supply. Thus, a diet supplying the cancer patient with sufficient fat and protein for his demands while restricting the carbohydrates (CHO) tumors thrive on, could be a helpful strategy in improving the patients’ situation. A ketogenic diet (KD) fulfills these requirements. Therefore, we performed a pilot study to investigate the feasibility of a KD and its influence on the quality of life of patients with advanced metastatic tumors. Methods: Sixteen patients with advanced metastatic tumors and no conventional therapeutic options participated in the study. The patients were instructed to follow a KD (less than 70 g CHO per day) with normal groceries and were provided with a supply of food additives to mix a protein/fat shake to simplify the 3-month intervention period. Quality of life [assessed by EORTC QLQ-C30 (version 2)], serum and general health parameters were determined at baseline, after every two weeks of follow-up, or after drop out. The effect of dietary change on metabolism was monitored daily by measuring urinary ketone bodies. Results: One patient did not tolerate the diet and dropped out within 3 days. Among those who tolerated the diet, two patients died early, one stopped after 2 weeks due to personal reasons, one felt unable to stick to the diet after 4 weeks, one stopped after 6 and two stopped after 7 and 8 weeks due to progress of the disease, one had to discontinue after 6 weeks to resume chemotherapy and five completed the 3 month intervention period. These five and the one who resumed chemotherapy after 6 weeks report an improved emotional functioning and less insomnia, while several other parameters of quality of life remained stable or worsened, reflecting their very advanced disease. Except for temporary constipation and fatigue, we found no severe adverse side effects, especially no changes in cholesterol or blood lipids. Conclusions: These pilot data suggest that a KD is suitable for even advanced cancer patients. It has no severe side effects and might improve aspects of quality of life and blood parameters in some patients with advanced metastatic tumors.
Background
The viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).
Methods
This is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay.
Results
Most patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009).
Conclusions
COVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity.
Aim:
This randomized controlled trial assessed the impact of Lactobacillus reuteri on pregnancy gingivitis in healthy women.
Materials and Methods:
Forty-five healthy women (24 test/21 placebo) with pregnancy gingivitis in the third trimester of pregnancy were enrolled. At baseline Gingival Index (GI) and Plaque Index (PlI) were assessed at the Ramfjord teeth and venous blood taken for TNF-alpha analysis. Subsequently participants were randomly provided with lozenges to be consumed 2 9 daily until birth (approx. 7 weeks) containing >= 10(8) CFU L. reuteri ATCC PTA 5289 and >= 10(8) CFU L. reuteri DSM 17938 (test) or being devoid of L. reuteri (placebo). Within 2 days after birth recording of GI, PlI and blood sampling were repeated.
Results:
At baseline, mean GI and mean PlI did not differ significantly between both groups. In the test group mean TNF-alpha serum level was significantly (p < 0.02) lower than in the placebo group. At reevaluation, mean GI and mean PlI of the test group were both significantly (p < 0.0001) lower than in the placebo group. Mean TNF-alpha serum level did no longer differ significantly between the groups.
Conclusions:
The consumption of L. reuteri lozenges may be a useful adjunct in the control of pregnancy gingivitis.
Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15%) discontinued the diet for poor tolerability. No serious adverse events attributed to the diet were observed. Urine ketosis was achieved at least once in 12 of 13 (92%) evaluable patients. One patient achieved a minor response and two patients had stable disease after 6 weeks. Median PFS of all patients was 5 (range, 3-13) weeks, median survival from enrollment was 32 weeks. The trial allowed to continue the diet beyond progression. Six of 7 (86%) patients treated with bevacizumab and diet experienced an objective response, and median PFS on bevacizumab was 20.1 (range, 12-124) weeks, for a PFS at 6 months of 43%. In the mouse glioma model, ketogenic diet alone had no effect on median survival, but increased that of bevacizumab-treated mice from 52 to 58 days (p<0.05). In conclusion, a ketogenic diet is feasible and safe but probably has no significant clinical activity when used as single agent in recurrent glioma. Further clinical trials are necessary to clarify whether calorie restriction or the combination with other therapeutic modalities, such as radiotherapy or anti-angiogenic treatments, could enhance the efficacy of the ketogenic diet.
Candida albicans and Candida dubliniensis are pathogenic fungi that are highly related but differ in virulence and in some phenotypic traits. During in vitro growth on certain nutrient-poor media, C. albicans and C. dubliniensis are the only yeast species which are able to produce chlamydospores, large thick-walled cells of unknown function. Interestingly, only C. dubliniensis forms pseudohyphae with abundant chlamydospores when grown on Staib medium, while C. albicans grows exclusively as a budding yeast. In order to further our understanding of chlamydospore development and assembly, we compared the global transcriptional profile of both species during growth in liquid Staib medium by RNA sequencing. We also included a C. albicans mutant in our study which lacks the morphogenetic transcriptional repressor Nrg1. This strain, which is characterized by its constitutive pseudohyphal growth, specifically produces masses of chlamydospores in Staib medium, similar to C. dubliniensis. This comparative approach identified a set of putatively chlamydospore-related genes. Two of the homologous C. albicans and C. dubliniensis genes (CSP1 and CSP2) which were most strongly upregulated during chlamydospore development were analysed in more detail. By use of the green fluorescent protein as a reporter, the encoded putative cell wall related proteins were found to exclusively localize to C. albicans and C. dubliniensis chlamydospores. Our findings uncover the first chlamydospore specific markers in Candida species and provide novel insights in the complex morphogenetic development of these important fungal pathogens.
Background
Fermented wheat germ extract (FWGE) sold under the trade name Avemar exhibits anticancer activity in vitro and in vivo. Its mechanisms of action are divided into antiproliferative and antimetabolic effects. Its influcence on cancer cell metabolism needs further investigation. One objective of this study, therefore, was to further elucidate the antimetabolic action of FWGE. The anticancer compound 2,6-dimethoxy-1,4-benzoquinone (DMBQ) is the major bioactive compound in FWGE and is probably responsible for its anticancer activity. The second objective of this study was to compare the antiproliferative properties in vitro of FWGE and the DMBQ compound.
Methods
The IC\(_{50}\) values of FWGE were determined for nine human cancer cell lines after 24 h of culture. The DMBQ compound was used at a concentration of 24 μmol/l, which is equal to the molar concentration of DMBQ in FWGE. Cell viability, cell cycle, cellular redox state, glucose consumption, lactic acid production, cellular ATP levels, and the NADH/NAD\(^+\) ratio were measured.
Results
The mean IC\(_{50}\) value of FWGE for the nine human cancer cell lines tested was 10 mg/ml. Both FWGE (10 mg/ml) and the DMBQ compound (24 μmol/l) induced massive cell damage within 24 h after starting treatment, with changes in the cellular redox state secondary to formation of intracellular reactive oxygen species. Unlike the DMBQ compound, which was only cytotoxic, FWGE exhibited cytostatic and growth delay effects in addition to cytotoxicity. Both cytostatic and growth delay effects were linked to impaired glucose utilization which influenced the cell cycle, cellular ATP levels, and the NADH/NAD\(^+\) ratio. The growth delay effect in response to FWGE treatment led to induction of autophagy.
Conclusions
FWGE and the DMBQ compound both induced oxidative stress-promoted cytotoxicity. In addition, FWGE exhibited cytostatic and growth delay effects associated with impaired glucose utilization which led to autophagy, a possible previously unknown mechanism behind the influence of FWGE on cancer cell metabolism.
Background: Hyaluronan (HA), a component of the extracellular matrix, is frequently increased under pathological conditions including cancer. Not only stroma cells but also cancer cells themselves synthesize HA, and the interaction of HA with its cognate receptors promotes malignant progression and metastasis. Methods: In the present study, HA deposition in tissue sections was analyzed by hyaluronan-binding protein (HABP) ligand histochemistry in 17 borderline tumors and 102 primary and 20 recurrent ovarian cancer samples. The intensity and, particularly, localization of the HA deposition were recorded: for the localization, the pericellular deposition around the ovarian cancer cells was distinguished from the deposition within the stromal compartment. These histochemical data were correlated with clinical and pathological parameters. Additionally, within a reduced subgroup of ovarian cancer samples (n = 70), the RNA levels of several HA-associated genes were correlated with the HA localization and intensity. Results: Both stroma-localized and pericellular tumor-cell-associated HA deposition were observed. Cancer-cell pericellular HA deposition, irrespective of its staining intensity, was significantly associated with malignancy, and in the primary ovarian cancer cohort, it represents an independent unfavorable prognostic marker for overall survival. Furthermore, a significant association between high CD44, HAS2 and HAS3 mRNA levels and a cancer-cell pericellular HA-deposition pattern was noted. In contrast, stromal hyaluronan deposition had no impact on ovarian cancer prognosis. Conclusions: In conclusion, the site of HA deposition is of prognostic value, but the amount deposited is not. The significant association of only peritumoral cancer-cell HA deposition with high CD44 mRNA expression levels suggests a pivotal role of the CD44–HA signaling axis for malignant progression in ovarian cancer.
Objectives
The severity of Coronavirus Disease 2019 (COVID-19) is largely determined by the immune response. First studies indicate altered lymphocyte counts and function. However, interactions of pro- and anti-inflammatory mechanisms remain elusive. In the current study we characterized the immune responses in patients suffering from severe COVID-19-induced acute respiratory distress syndrome (ARDS).
Methods
This was a single-center retrospective study in patients admitted to the intensive care unit (ICU) with confirmed COVID-19 between March 14th and May 28th 2020 (n = 39). Longitudinal data were collected within routine clinical care, including flow-cytometry of lymphocyte subsets, cytokine analysis and growth differentiation factor 15 (GDF-15). Antibody responses against the receptor binding domain (RBD) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein were analyzed.
Results
All patients suffered from severe ARDS, 30.8% died. Interleukin (IL)-6 was massively elevated at every time-point. The anti-inflammatory cytokine IL-10 was concomitantly upregulated with IL-6. The cellular response was characterized by lymphocytopenia with low counts of CD8+ T cells, natural killer (NK) and naïve T helper cells. CD8+ T and NK cells recovered after 8 to 14 days. The B cell system was largely unimpeded. This coincided with a slight increase in anti-SARS-CoV-2-Spike-RBD immunoglobulin (Ig) G and a decrease in anti-SARS-CoV-2-Spike-RBD IgM. GDF-15 levels were elevated throughout ICU treatment.
Conclusions
Massively elevated levels of IL-6 and a delayed cytotoxic immune defense characterized severe COVID-19-induced ARDS. The B cell response and antibody production were largely unimpeded. No obvious imbalance of pro- and anti-inflammatory mechanisms was observed, with elevated GDF-15 levels suggesting increased tissue resilience.
Background
Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known about the effect of adenosine on myeloid cells. Considering that tumor associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) constitute up to 20 % of OvCA tissue, we investigated the effect of adenosine on myeloid cells and explored a possible contribution of myeloid cells to adenosine generation in vitro and ex vivo.
Methods
Monocytes were used as human blood-derived myeloid cells. After co-incubation with SK-OV-3 or OAW-42 OvCA cells, monocyte migration was determined in transwell assays. For conversion into M2-polarized “TAM-like” macrophages, monocytes were co-incubated with OAW-42 cells. Ex vivo TAMs were obtained from OvCA ascites. Macrophage phenotypes were investigated by intracellular staining for IL-10 and IL-12. CD39 and CD73 expression were assessed by FACS analysis both on in vitro-induced TAM-like macrophages and on ascites-derived ex situ-TAMs. Myeloid cells in solid tumor tissue were analyzed by immunohistochemistry. Generation of biologically active adenosine by TAM-like macrophages was measured in luciferase-based reporter assays. Functional effects of adenosine were investigated in proliferation-experiments with CD4+ T cells and specific inhibitors.
Results
When CD39 or CD73 activity on OvCA cells were blocked, the migration of monocytes towards OvCA cells was significantly decreased. In vivo, myeloid cells in solid ovarian cancer tissue were found to express CD39 whereas CD73 was mainly detected on stromal fibroblasts. Ex situ-TAMs and in vitro differentiated TAM-like cells, however, upregulated the expression of CD39 and CD73 compared to monocytes or M1 macrophages. Expression of ectonucleotidases also translated into increased levels of biologically active adenosine. Accordingly, co-incubation with these TAMs suppressed CD4+ T cell proliferation which could be rescued via blockade of CD39 or CD73.
Conclusion
Adenosine generated by OvCA cells likely contributes to the recruitment of TAMs which further amplify adenosine-dependent immunosuppression via additional ectonucleotidase activity. In solid ovarian cancer tissue, TAMs express CD39 while CD73 is found on stromal fibroblasts. Accordingly, small molecule inhibitors of CD39 or CD73 could improve immune responses in ovarian cancer.